Our previous studies have shown that inclusion of a tumor antigen within VSV induces CD8+ T cell dependent anti-tumor therapy directed specifically against the virally encoded antigen as a result of the potent immune stimulating adjuvant properties of infection with VSV19, 34, 35, 36. The gene discussed is CD8A; the disease is neoplasm.